Evagelos Coskinas, MD
Psychiatry · Riverside, CANPI 1437382314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Livanova USA, Inc. at 34.4% of the total. 2024 is the largest year on record at $498, 5.4 times the $92 reported in 2019.
Across 21 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$298
- Teva Pharmaceuticals USA, Inc.$163
- E.r. Squibb & Sons, L.L.C.$119
- Otsuka America Pharmaceutical, Inc.$75
- Alkermes, Inc.$67
- Johnson & Johnson$52
- plus $93 from 3 others
Across 665 payments — averaging $10,933 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$4.7M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.3M
- AbbVie$417K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$262K
- Boehringer Ingelheim$195K
- Teva Pharmaceuticals USA, Inc.$168K
- plus $226K from 7 others
What the payments were for
- Food & beverage$866100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 3 | $298 |
| Teva Pharmaceuticals USA, Inc. | 4 | $163 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Alkermes, Inc. | 3 | $67 |
| Johnson & Johnson | 2 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| Indivior Inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$866 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naloxone Hcl | 14 | $865 |
| Olanzapine | 32 | $649 |
| Quetiapine Fumarate | 14 | $322 |
| Bupropion Hcl SrBupropion Hcl | 15 | $239 |
| Gabapentin | 11 | $142 |
| Alprazolam | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Riverside
- Ramesh PatelRiverside$112K
- Deepak RajpootRiverside$109K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.